Download PDF
TumorDiagnostik & Therapie 2012; 33(02): 95-102
DOI: 10.1055/s-0031-1299347
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelles chirurgisches Vorgehen bei kolorektalen Lebermetastasen

Current Surgical Therapy for Colorectal Liver Metastases
P. Gassmann
  Klinik und Poliklinik für Allgemein und Abdominalchirurgie, Universitätsmedizin der Johannes Gutenberg-Universität, Mainz
,
H. Lang
  Klinik und Poliklinik für Allgemein und Abdominalchirurgie, Universitätsmedizin der Johannes Gutenberg-Universität, Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
14 March 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das kolorektale Karzinom steht sowohl bei der Inzidenz als auch der tumorbedingten Sterblichkeit an zweiter Stelle der soliden Karzinome in der westlichen Welt. Bei etwa der Hälfte der Patienten mit einem kolorektalen Karzinom muss im Verlauf der Erkrankung mit Lebermetastasen gerechnet werden, wobei ein Drittel dieser Patienten eine isoliert hepatische Metastasierung aufweist. Die einzige potenziell kurative Therapie kolorektaler Lebermetastasen ist derzeit die Leberresektion. Voraussetzung für die Indikationsstellung zur Leberresektion ist die Möglichkeit, eine R0-Resektion unter Erhalt eines ausreichenden funktionellen Restlebervolumens erreichen zu können. Nur etwa 20 – 25%  der Patienten mit kolorektalen Lebermetastasen qualifizieren sich für eine primäre Leberresektion. Durch die Kombination verschiedener Verfahren und multimodaler Therapiekonzepte, wie z. B. 2-zeitige Leberresektionen oder neoadjuvante Chemotherapie zum ‚Downsizing’, kann der Anteil sekundär resezierbarer Metastasen um etwa 10 – 20%  erweitert werden. Die chirurgische Morbidität und Mortalität werden in aktuellen Studien mit 30 – 40%  und 1 – 2%  angegeben. Nach R0-Resektion kann, je nach Patientenselektion, mit einer tumorfreien 3-Jahres-Überlebensrate von ~35%  und einer 5- und 10-Jahres-Überlebensrate von ~45%  und ~25%  gerechnet werden. Dabei ist der wichtigste Prognosefaktor für das Langzeitüberleben ein tumorfreier Resektionsrand. Die Etablierung multimodaler Therapiekonzepte hat bis heute zu einer stetigen Zunahme des Anteils resezierbarer Metastasen und somit zu einer signifikanten Verbesserung der Prognose von Patienten mit kolorektalen Lebermetastasen geführt. Durch neue, Antikörper-basierte systemische Therapien ist für die nächsten Jahre eine Fortsetzung dieses Trends zu erwarten.

Abstract

Colorectal Cancer is the second most common cancer in the western world and about half of patients will develop liver metastases (CRLM) in the course of the disease. Complete liver resection is the only potentially curative therapy available to date. In first line, only 20%  of patients with colorectal liver metastases qualify for surgery. Surgery is indicated in cases when complete resection with tumor free resection margins can be achieved under preservation of a functionally sufficient remnant liver volume with undisturbed perfusion and biliary drainage. By modern multimodality treatment, another 10 – 20%  of metastases can be converted to a ‘secondary resectable’ stage, e. g. by 2 stage hepatectomy or downsizing of the metastases by neoadjuvant chemotherapy. Surgical morbidity and mortality in recent literature is 30 – 40%  and 1 – 2% , respectively. Depending on selection criteria, the progression-free 3-year survival rate is about 35% , and the 5- and 10-years overall survival rate is about 45%  und 25% , respectively. The most important prognostic factor for patients with CRLM is a tumor free resection margin. The evolvement of multimodality treatment algorithms led to a continuously increasing number of resectable metastases with subsequently improving prognosis for liver metastatic colorectal cancer. Due to the availability of new antibody based systemic therapies, further prognostic improvements can be expected for patients with CRLM.

Schlüsselwörter

Leberresektion - neoadjuvante Chemotherapie - Down-sizing - laparoskopische Leberresektion

Key words

liver resection - neoadjuvant chemotherapy - down-sizing - laproscopic liver resection
 

  • Literatur

  • 1 Abu Hilal M, Underwood T, Zuccaro M et al. Short- and medium-term results of totally laparoscopic resection for colorectal liver metastases. Br J Surg 2010; 97: 927-933
    CrossrefPubMedGoogle Scholar
  • 2 Abulkhir A, Limongelli P, Healey AJ et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247: 49-57
    CrossrefPubMedGoogle Scholar
  • 3 Adam R, Bismuth H, Castaing D et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225: 51-60
    CrossrefPubMedGoogle Scholar
  • 4 Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657
    Google Scholar
  • 5 Adam R, Pascal G, Azoulay D et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003; 238: 871-883
    CrossrefPubMedGoogle Scholar
  • 6 Adam R, Aloia T, Lévi F et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. Clin Oncol 2007; 25: 4593-4602
    CrossrefPubMedGoogle Scholar
  • 7 Adson MA, Van Heerden JA. Major hepatic resections for metastatic colorectal cancer. Ann Surg 1980; 191: 576-583
    CrossrefPubMedGoogle Scholar
  • 8 Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. Clin Oncol 2005; 23: 9243-9249
    CrossrefPubMedGoogle Scholar
  • 9 André T, Boni C, Mounedji-Boudiaf L et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
    CrossrefPubMedGoogle Scholar
  • 10 Aussilhou B, Dokmak S, Faivre S et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009; 16: 1553-1559
    CrossrefPubMedGoogle Scholar
  • 11 Balzan S, Belghiti J, Farges O et al. The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005; 242: 824-828
    CrossrefPubMedGoogle Scholar
  • 12 Belghiti J, Hiramatsu K, Benoist S et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46
    CrossrefPubMedGoogle Scholar
  • 13 Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231: 743-751
    CrossrefPubMedGoogle Scholar
  • 14 Borasio P, Gisabella M, Billé A et al. Role of surgical resection in colorectal lung metastases: analysis of 137 patients. Int J Colorectal Dis 2011; 26: 183-190
    CrossrefPubMedGoogle Scholar
  • 15 van Buren 2nd G, Yang AD, Dallas NA et al. Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008; 26: 1836-1842
    CrossrefPubMedGoogle Scholar
  • 16 Carpizo DR, Are C, Jarnagin W et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009; 16: 2138-2146
    CrossrefPubMedGoogle Scholar
  • 17 Castaing D, Vibert E, Ricca L et al. Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers. Ann Surg 2009; 250: 849-855
    CrossrefPubMedGoogle Scholar
  • 18 Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766
    CrossrefPubMedGoogle Scholar
  • 19 Couinaud C. Le Foie: Etudes anatomicales et chirurgicales. Masson; Paris, France: 1957. pp 187-208
    Google Scholar
  • 20 Elias D, Cavalcanti A, Sabourin JC et al. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998; 69: 88-93
    CrossrefPubMedGoogle Scholar
  • 21 Elias D, Sideris L, Pocard M et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004; 11: 274-280
    CrossrefPubMedGoogle Scholar
  • 22 Fernandez FG, Drebin JA, Linehan DC et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447
    CrossrefPubMedGoogle Scholar
  • 23 Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
    CrossrefPubMedGoogle Scholar
  • 24 Fong Y, Cohen AM, Fortner JG et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946
    CrossrefPubMedGoogle Scholar
  • 25 Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318
    CrossrefPubMedGoogle Scholar
  • 26 Gomez D, Malik HZ, Bonney GK et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 2007; 94: 1395-1402
    CrossrefPubMedGoogle Scholar
  • 27 de Haas RJ, Wicherts DA, Flores E et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?. Ann Surg 2008; 248: 626-637
    PubMedGoogle Scholar
  • 28 Ito H, Are C, Gonen M et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247: 994-1002
    CrossrefPubMedGoogle Scholar
  • 29 Iwatsuki S, Dvorchik I, Madariaga JR et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299
    CrossrefPubMedGoogle Scholar
  • 30 Jaeck D, Nakano H, Bachellier P et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002; 9: 430-438
    CrossrefPubMedGoogle Scholar
  • 31 Jonas S, Thelen A, Benckert C et al. Extended resections of liver metastases from colorectal cancer. World J Surg 2007; 31: 511-521
    CrossrefPubMedGoogle Scholar
  • 32 Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7
    Google Scholar
  • 33 Kattan MW, Gönen M, Jarnagin WR et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247: 282-287
    CrossrefPubMedGoogle Scholar
  • 34 Kazaryan AM, Marangos IP, Røsok BI et al. Laparoscopic resection of colorectal liver metastases: surgical and long-term oncologic outcome. Ann Surg 2010; 252: 1005-1012
    CrossrefPubMedGoogle Scholar
  • 35 Kesmodel SB, Ellis LM, Lin E et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260
    CrossrefPubMedGoogle Scholar
  • 36 Klinger M, Tamandl D, Eipeldauer S et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010; 17: 2059-2065
    CrossrefPubMedGoogle Scholar
  • 37 Koffron AJ, Auffenberg G, Kung R et al. Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 2007; 246: 385-392
    CrossrefPubMedGoogle Scholar
  • 38 Kokudo N, Miki Y, Sugai S et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137: 833-840
    CrossrefPubMedGoogle Scholar
  • 39 Konopke R, Kersting S, Makowiec F et al. Resection of colorectal liver metastases: is a resection margin of 3 mm enough?: a multicenter analysis of the GAST Study Group. World J Surg 2008; 32: 2047-2056
    CrossrefPubMedGoogle Scholar
  • 40 Kooby DA, Fong Y, Suriawinata A et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-1044
    CrossrefPubMedGoogle Scholar
  • 41 Lambert LA, Colacchio TA, Barth Jr RJ. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000; 135: 473-479
    CrossrefPubMedGoogle Scholar
  • 42 Lang H, Radtke A, Hindennach M et al. Impact of virtual tumor resection and computer-assisted risk analysis on operation planning and intraoperative strategy in major hepatic resection. Arch Surg 2005; 140: 629-638
    CrossrefPubMedGoogle Scholar
  • 43 Lang H, Sotiropoulos GC, Brokalaki EI et al. Left hepatic trisectionectomy for hepatobiliary malignancies. J Am Coll Surg 2006; 203: 311-321
    CrossrefPubMedGoogle Scholar
  • 44 Law WL, Choi HK, Lee YM et al. The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol 2007; 14: 2559-2566
    CrossrefPubMedGoogle Scholar
  • 45 Martin R, Paty P, Fong Y et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003; 197: 233-241
    CrossrefPubMedGoogle Scholar
  • 46 McCormack L, Petrowsky H, Jochum W et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007; 245: 923-930
    CrossrefPubMedGoogle Scholar
  • 47 Merkel S, Bialecki D, Meyer T et al. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol 2009; 100: 349-357
    CrossrefPubMedGoogle Scholar
  • 48 Morris EJ, Forman D, Thomas JD et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97: 1110-1118
    CrossrefPubMedGoogle Scholar
  • 49 Musholt TJ, Lang H. Indikatorisches und operatives Spektrum bei neuroendokrinen Lebermetastasen. Chirurg 2009; 80: 113-121
    CrossrefPubMedGoogle Scholar
  • 50 Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int 2010; 107: 335-342
    PubMedGoogle Scholar
  • 51 Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1 568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262
    CrossrefPubMedGoogle Scholar
  • 52 Nordlinger B, Vaillant JC, Guiguet M et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12: 1491-1496
    PubMedGoogle Scholar
  • 53 Nordlinger B, Sorbye H, Glimelius B et al. EORTC Gastro-Intestinal Tract Cancer Group. Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
    CrossrefPubMedGoogle Scholar
  • 54 Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection – 2 804 patients. Ann Surg 2009; 250: 831-841
    CrossrefPubMedGoogle Scholar
  • 55 Pathak S, Sarno G, Nunes QM et al. Synchronous resection for colorectal liver metastases: the future. Eur J Surg Oncol 2010; 36: 1044-1046
    CrossrefPubMedGoogle Scholar
  • 56 Pawlik TM, Olino K, Gleisner AL et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868
    CrossrefPubMedGoogle Scholar
  • 57 Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-722
    CrossrefPubMedGoogle Scholar
  • 58 Pawlik TM, Vauthey JN. Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome. Ann Surg Oncol 2008; 15: 677-679
    CrossrefPubMedGoogle Scholar
  • 59 Petrowsky H, Gonen M, Jarnagin W et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235: 863-871
    CrossrefPubMedGoogle Scholar
  • 60 Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007; 84: 324-338
    CrossrefPubMedGoogle Scholar
  • 61 Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982
    CrossrefPubMedGoogle Scholar
  • 62 Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939
    CrossrefPubMedGoogle Scholar
  • 63 Reddy SK, Pawlik TM, Zorzi D et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14: 3481-3491
    CrossrefPubMedGoogle Scholar
  • 64 Reissfelder C, Rahbari NN, Koch M et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 2009; 16: 3279-3288
    CrossrefPubMedGoogle Scholar
  • 65 Ribero D, Wang H, Donadon M et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761-2767
    CrossrefPubMedGoogle Scholar
  • 66 Ribero D, Abdalla EK, Madoff DC et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94: 1386-1394
    CrossrefPubMedGoogle Scholar
  • 67 Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246
    CrossrefPubMedGoogle Scholar
  • 68 Schmiegel W, Pox C, Reinacher-Schick A et al. Federal Committee of Physicians and Health Insurers. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 2010; 48: 65-136
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol). 1997. 9. 248-251
    Google Scholar
  • 70 Strasberg SM, Linehan DC, Hawkins WG. The accordion severity grading system of surgical complications. Ann Surg 2009; 250: 177-186
    CrossrefPubMedGoogle Scholar
  • 71 Sugarbaker PH. Repeat hepatectomy for colorectal metastases. J Hepatobiliary Pancreat Surg 1999; 6: 30-38
    CrossrefPubMedGoogle Scholar
  • 72 Tanaka K, Shimada H, Matsuo K et al. Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 2007; 33: 329-335
    CrossrefPubMedGoogle Scholar
  • 73 Tanaka K, Kumamoto T, Matsuyama R et al. Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg 2010; 14: 359-368
    CrossrefPubMedGoogle Scholar
  • 74 Tamandl D, Gruenberger B, Klinger M et al. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 2010; 252: 124-130
    CrossrefPubMedGoogle Scholar
  • 75 Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072
    Google Scholar
  • 76 Vigano L, Laurent A, Tayar C et al. The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg 2009; 250: 772-782
    CrossrefPubMedGoogle Scholar
  • 77 Welsh FK, Tekkis PP, John TG et al. Open liver resection for colorectal metastases: better short- and long-term outcomes in patients potentially suitable for laparoscopic liver resection. HPB (Oxford) 2010; 12: 188-194
    CrossrefPubMedGoogle Scholar
  • 78 Welsh FK, Tilney HS, Tekkis PP et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96: 1037-1042
    CrossrefPubMedGoogle Scholar
  • 79 Wieser M, Sauerland S, Arnold D et al. Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer 2010; 10: 309
    CrossrefPubMedGoogle Scholar
  • 80 Zorzi D, Mullen JT, Abdalla EK et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006; 10: 86-94
    CrossrefPubMedGoogle Scholar
  • 81 Zorzi D, Laurent A, Pawlik TM et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-286
    CrossrefPubMedGoogle Scholar